Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017)

Arbutus Biopharma's (ABUS) quarterly Non-Current Debt came in at $12.0 million in Q4 2017, little changed year-on-year from $12.0 million in Q4 2016, and little changed quarter-over-quarter from $12.0 million in Q3 2017.

Arbutus Biopharma (ABUS) Non-Current Debt (2016 - 2017) Analysis & Trends

Arbutus Biopharma has disclosed Non-Current Debt across 2 years of filings, most recently posting $12.0 million for Q4 2017.

  • Non-Current Debt for Q4 2017 came in at $12.0 million, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2017 was $12.0 million (changed 0.0% YoY), and the FY2017 annual result was $12.0 million, changed 0.0% from the prior year.
  • Non-Current Debt came in at $12.0 million for Q4 2017 at Arbutus Biopharma, roughly flat from $12.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $12.0 million in Q4 2016 to a low of $12.0 million in Q4 2016.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Arbutus Biopharma 882.62 Mn 882.62 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 12.00 Mn
Dec 31, 2017 12.00 Mn
Sep 30, 2017 12.00 Mn
Sep 30, 2017 12.00 Mn
Jun 30, 2017 12.00 Mn
Jun 30, 2017 12.00 Mn
Mar 31, 2017 12.00 Mn
Mar 31, 2017 12.00 Mn
Dec 31, 2016 12.00 Mn
Dec 31, 2016 12.00 Mn